Who is sponsoring NCT03807973?

NCT03807973 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT03807973?

Interventions in NCT03807973: [Zr-89]Oxine-labeled leukocytes PET/MRI.

What condition does NCT03807973 study?

NCT03807973 studies Fibromyalgia, Chronic Fatigue Syndrome, Multiple Sclerosis, Healthy.

Is NCT03807973 still recruiting?

NCT03807973 is currently suspended. Last updated 30 May 2026.

Last reviewed 2026-05-30 · How we verify

NCT03807973

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.

Suspended Phase 1 Last updated 30 May 2026

What this trial tests

Phase 1 trial testing [Zr-89]Oxine-labeled leukocytes PET/MRI in Fibromyalgia in 120 participants. Suspended.

Timeline

5 October 2021

Primary endpoint
1 October 2028

1 October 2028

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	Phase 1
Status	Suspended
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	120
Start date	5 October 2021
Primary completion	1 October 2028
Estimated completion	1 October 2028
Sites	1 location across United States

Drugs / interventions tested

[Zr-89]Oxine-labeled leukocytes PET/MRI — full drug profile →

Conditions studied

Fibromyalgia — all drugs for Fibromyalgia →
Chronic Fatigue Syndrome — all drugs for Chronic Fatigue Syndrome →
Multiple Sclerosis — all drugs for Multiple Sclerosis →
Healthy — all drugs for Healthy →

Sponsor

University of Alabama at Birmingham

Who can join

Adults 18 to 65, any sex, with Fibromyalgia or Chronic Fatigue Syndrome. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Regional brain distribution of radiolabeled white blood cells
Time frame: 3 years
Descriptive statistics (means and standard deviations) of standardized uptake values (SUVs) will be presented for the patient groups and healthy controls in the following regions: whole brain, gray matter, white matter, atlas-based regions of interest, and lesions (MS patients only). Normality of the SUV distribution will be tested using Shapiro-Wilk tests, and the data will be transformed to norm

Sponsor's own description

This study will use brain Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) and an investigational radioactive drug called \[Zr-89\]oxine to track the location of white blood cells (also called leukocytes) in the body. PET/MRI will be used to visualize labeled white blood cells and determine if they enter the central nervous system in conditions associated with brain inflammation (also called neuroinflammation). By better understanding the role of neuroinflammation in fibromyalgia, chronic fatigue syndrome, and multiple sclerosis, the investigator hopes to be able to better diagnose and treat patients in the future.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Translational molecular imaging and drug development in multiple sclerosis.
Tay D, Ahmed H, Dawoud A, Salam M, et al · · 2026 · PMID 41356192 · DOI 10.7150/thno.119559

Verify or expand the search:

Other recruiting trials for Fibromyalgia

Currently open trials in the same condition.

NCT02285868 — ATI Evidence-based Guide Investigating Clinical Services · active not recruiting
NCT07245303 — Neural Mechanisms of Light Driven Analgesia · NA · recruiting
NCT05901259 — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes · recruiting
NCT07358754 — The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor · recruiting
NCT07465991 — The Effect of Digital Cognitive Behavioural Therapy for Insomnia on Physical Activity in Fibromyalgia · NA · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03807973 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 30 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03807973.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing